Epidemic situation of rabies and research progress on rabies vaccines for human use
SHEN Zheng-jun1, ZHAO Yu-liang2, ZHANG Jun1, WU Zhi-wei2, JIN Fei2
1. School of Public Health, North China University of Science and Technology, Tangshan, Hebei 063210, China; 2. Institute for Vaccine Clinical Research, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei 050021, China
Abstract:Rabies is one of the serious public health problems in the world, lacking effective treatment methods, and approximate 59,000 people die of rabies worldwide every year. Most developed countries or regions have basically eliminated canine-mediated human rabies, but the World Health Organization believes that there exists a certain scale of underestimation in the burden of rabies. So far, the Lyssavirus genus contains a total of 16 rabies-related viruses, and there are differences in distribution areas among different species. Understanding the curent status of rabies epidemic,prevention measures of human rabies, and the latest development of modern rabies vaccines is conducive to better formulating comprehensive prevention and control strategies for human rabies and promoting human health.
[1] World Health Organization. WHO expert consultation on rabies[M]. 3rd Report. Geneva:WHO Press, 2018. [2] Jackson AC. Rabies: scientific basis of the disease and its management[M]. 3rd ed. London: Elsevier Science, 2013. [3] International Committee on Taxonomy of Viruses. Genus: Lyssavirus[EB/OL]. [2019-06-13]. https://talk.ictvonline.org/ictv-reports/ictv_online_report/negative-sense-rna-viruses/mononegavirales/w/rhabdoviridae/795/genus-lyssavirus. [4] Amarasinghe GK,Ayllón MA, Bào Y, et al. Taxonomy of the order Mononegavirales: update 2019[J]. Arch Virol, 2019, 164(7):1967-1980. [5] Badrane H, Bahloul C, Perrin P, et al. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity[J]. J Virol, 2001, 75(7):3268-3276. [6] Fooks A.The challenge of new and emerging Lyssaviruses[J]. Expert Rev Vaccines, 2004, 3(4):333-336. [7] Gunawardena PS, Marston DA, Ellis RJ, et al. Lyssavirus in indian flying foxes, Sri Lanka[J].Emerg Infect Dis, 2016, 22(8):1456-1459. [8] Freuling CM, Beer M, Conraths FJ, et al. Novel Lyssavirus in Natterer's Bat, Germany[J]. Emerg Infect Dis, 2011, 17(8):1519-1522. [9] Kuzmin IV, Mayer AE, Niezgoda M, et al. Shimoni bat virus, a new representative of the Lyssavirus genus[J]. Virus Res, 2010, 149(2):197-210. [10] Marston DA, Horton DL, Ngeleja C, et al. Ikoma Lyssavirus, highly divergent novel Lyssavirus in an African civet[J]. Emerg Infect Dis, 2012, 18(4):664-667. [11] Marston DA, Ellis RJ, Wise EL, et al. Complete genome sequence of Lleida bat Lyssavirus[J/OL]. Genome Announc, 2017, 5(2)[2019-6-20]. https://doi.org/10.1128/genomeA.01427-16. [12] Horton DL, Banyard AC, Marston DA, et al. Antigenic and genetic characterization of a divergent African virus, Ikoma Lyssavirus[J]. J Gen Virol, 2014, 95(5):1025-1032. [13] Weyer J, Kuzmin IV, Rupprecht CE, et al. Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length Lyssavirus glycoprotein genes[J]. Epidemiol Infect, 2008, 136(5):670-678. [14] Hu SC, Hsu CL, Lee MS, et al. Lyssavirus in Japanese pipistrelle, Taiwan[J]. Emerg Infect Dis, 2018, 24(4):782-785. [15] Nokireki T, Tammiranta N, Kokkonen UM, et al. Tentative novel Lyssavirus in a bat in Finland[J]. Transbound Emerg Dis, 2018, 65(3):593-596. [16] Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies[J]. PLoS Negl Trop Dis, 2015, 9(4):e0003709. [17] Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia[J]. Bull World Health Organ, 2005, 83(5):360-368. [18] Fooks AR, Banyard AC, Horton DL, et al. Current status of rabies and prospects for elimination[J].Lancet, 2014, 384(9951):1389-1399. [19] Shwiff S, Hampson K, Anderson A. Potential economic benefits of eliminating canine rabies[J]. Antiviral Res, 2013, 98(2):352-356. [20] Mallewa M, Fooks AR, Banda D, et al. Rabies encephalitis in malaria-endemic area, Malawi, Africa[J]. Emerg Infect Dis, 2007, 13(1):136-139. [21] 陈浩川, 旷翠萍, 谢旭,等. 深圳市犬(动物)伤暴露人群监测系统评价[J].实用预防医学, 2019, 26(12):1466-1469. [22] Dodet B, Korejwo J, Briggs DJ. Eliminating the scourge of dog-transmitted rabies[J]. Vaccine, 2013, 31(10):1359. [23] Jibat T, Hogeveen H, Mourits MC. Review on dog rabies vaccination coverage in Africa: a question of dog accessibility or cost recovery?[J]. PLoS Negl Trop Dis, 2015, 9(2):e0003447. [24] Vigilato MA, Clavijo A, Knobl T, et al. Progress towards eliminating canine rabies:policies and perspectives from Latin America and the Caribbean[J]. Philos Trans R Soc Lon B Biol Sci, 2013, 368(1623):20120143. [25] World Health Organization. Human rabies:2016 updates and call for data[J]. Wkly Epidemiol Rec, 2017, 92(7):77-86. [26] Carrara P, Parola P, Brouqui P, et al. Imported human rabies cases worldwide, 1990-2012[J]. PLoS Negl Trop Dis, 2013, 7(5):e2209. [27] Cliquet F, Picard-Meyer E, Robardet E. Rabies in Europe: what are the risks[J]. Expert Rev Anti Infect Ther, 2014, 12(8):905-908. [28] Pieracci EG, Pearson CM, Wallace RM, et al. Vital signs: trends in human rabies deaths and exposures-United States, 1938-2018[J]. MMWR Morb Mort Wkly Rep, 2019, 68(23):524-528. [29] Birhane MG, Cleaton JM, Monroe BP, et al. Rabies surveillance in the United States during 2015[J]. J Am Vet Med Assoc, 2017, 250(10):1117-1130. [30] 孙永波,李滨.1990—2014年中国狂犬病流行态势和防护问题[J].中国全科医学,2016,19(5):570-573. [31] 孟凡东,吴迪,隋承光.2004—2015年中国狂犬病发病数据ARIMA乘积季节模型的建立及预测[J].中国卫生统计,2016,33(3):389-391,395. [32] 李艳荣.中国狂犬病2007—2016年流行特征及流行趋势预测[D].佳木斯:佳木斯大学,2018. [33] 周航,李昱,牟笛,等.中国2012年狂犬病流行特征分析[J].中华流行病学杂志,2015,36(3):205-209. [34] 刘佳佳,朵林,陶晓燕,等.中国2017年狂犬病流性特征分析[J].中华流行病学杂志,2019,40(5):526-530. [35] Zhao JH, Zhao LF, Liu F, et al. Ferret badger rabies in Zhejiang, Jiangxi and Taiwan, China[J]. Arch Virol, 2019, 164(2):579-584. [36] 赵铠,章以浩,李河民.医学生物制品学[M]. 第2版.北京:中国医药科技出版社, 2007. [37] Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies:recommendations of the advisory committee on immunization practices[J]. MMWR Recomm Rep, 2010, 59(RR-2):1-9. [38] 林海祥,Perrin P.铝佐剂对实验狂犬病疫苗的影响[J].中华实验和临床病毒学杂志,1999,13(2):133-135. [39] DiStefano D, Antonello JM, Bett AJ, et al. Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIXTM adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques[J]. Vaccine, 2013, 31(42):4888-4893. [40] Li X, Aldayel AM, Cui Z. Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles[J]. J Control Release, 2014, 173:148-157. [41] Shi W, Kou Y, Xiao J, et al. Comparison of immunogenicity, efficacy and transcriptome changes of inactivates rabies virus vaccine with different adjuvants[J]. Vaccine, 2018, 36(33):5020-5029. [42] Zhang Y, Zhang S, Li W, et al. A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies[J]. Virology, 2016, 489:165-172. [43] Wijaya L, Tham CYL, Chan YFZ, et al. An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers[J]. Vaccine, 2017, 35(8):1175-1183. [44] Kalimuddin S, Wijaya L, Chan YFZ, et al. A phaseⅡrandomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen[J]. Vaccine, 2017, 35(51):7127-7232. [45] Liu R, Wang J, Yang Y, et al. A novel rabies virus lipopeptide provides a better protection by improving the magnitude of DCs activation and T cell responses[J]. Virus Res, 2016, 221:66-73. [46] 周猛冲,李春明,李海龙,等.人用狂犬病疫苗的研究进展[J].中国生物制品学杂志, 2019, 32(1):119-123,128. [47] 郝晓芳,张加勇,徐佳,等.重组病毒载体疫苗的研究进展[J]. 黑龙江畜牧兽医, 2016, (13):68-71. [48] Rosales-Mendoza S. Current developments and future prospects for plant-made biopharmaceuticals against rabies[J]. Mol Biotechnol, 2015, 57(10):869-879. [49] Vrdoljak A, Allen EA, Ferrara F, et al. Induction of broad immunity by thermostabilized vaccines incorporated in dissolvable microneedles using novel fabrication methods[J]. J Control Release, 2016, 225:192-204. [50] van de Wijdeven GG, Hirschberg HJ, Weyers W, et al. Phase 1 clinical study with Bioneedles, a delivery platform for biopharmaceuticals[J]. Eur J Pharm Biopharm, 2015, 89:126-133. [51] 解庭波,明平刚,唐芳,等.狂犬病病毒CTN株反向遗传系统的改造及拯救[J]. 中国生物制品学杂志, 2015, 28(11):1121-1126.